BOSTON, March 4,
2024 /PRNewswire/ -- Elevation Oncology, Inc.
(Nasdaq: ELEV), an innovative oncology company focused on the
discovery and development of selective cancer therapies to treat
patients across a range of solid tumors with significant unmet
medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of
Directors.
"We are thrilled to welcome Julie and Alan as Elevation
Oncology's newest directors," said Steve
Elms, Chairman of Elevation Oncology. "Both are extremely
experienced drug developers, who have contributed to the
advancement and approval of multiple targeted therapies for the
treatment of cancer. On behalf of the Board, I look forward to
Julie and Alan's many insights into both clinical and regulatory
strategy as Elevation Oncology continues to advance its pipeline of
differentiated, potentially best-in-class antibody-drug conjugate
(ADC) therapies."
"I am excited to lend my expertise in drug development and
company building to help Elevation Oncology advance selective
cancer therapies to improve the care and treatment of patients with
solid tumors," said Dr. Cherrington. "With an initial update
from its ongoing Phase 1 clinical trial of EO-3021 on-track for
mid-year and the nomination of a HER3-ADC development candidate
expected before year-end, Elevation Oncology is on the precipice of
a significant transformation, and I look forward to partnering with
management to thoughtfully move both programs into later stages of
clinical and preclinical development, respectively."
"Now is an exciting time to join Elevation Oncology," said Dr.
Sandler. "In recent months, the company has focused its efforts on
developing a pipeline of differentiated ADCs to address
well-validated cancer targets that could potentially provide better
safety and efficacy to patients living with solid tumors. I am
eager to work closely with the team and to apply our collective
expertise in ADC and oncology drug discovery and development to
bring these novel medicines to patients with unmet needs."
Dr. Cherrington is an experienced life science executive with
extensive insight in bringing novel product candidates into the
clinic and through to commercialization. Over the course of her
career, Dr. Cherrington contributed to the successful development
of multiple U.S. Food and Drug Administration-approved products,
including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®, and
served as President and Chief Executive Officer (CEO) for several
biotechnology companies. She currently serves as a Venture Partner
at Brandon Capital Partners, as well as Chair of Actym
Therapeutics, Chair of Tolremo Therapeutics, and director at
Syncona Limited, Sardona Therapeutics, KisoJi Biotechnology and
MycRx. Earlier, Dr. Cherrington served as CEO of QUE Oncology, and
as President and CEO of Arch Oncology, Revitope Oncology, Inc.,
Zenith Epigenetics, and Pathway Therapeutics. Dr. Cherrington holds
a B.S. in Biology and an M.S. in Microbiology from the University of California, Davis, and completed her
Ph.D. training in Microbiology and Immunology at the University of Minnesota and Stanford University. She completed a postdoctoral
fellowship at the University of California,
San Francisco.
Dr. Sandler is an accomplished leader in oncology and drug
development, with experience leading clinical development and
operations, regulatory affairs, drug safety and asset development
strategy across industry and academia. He currently serves as
Executive Vice President and Chief Medical Officer of Mirati
Therapeutics, a Bristol Myers Squibb Company. Prior to joining
Mirati Therapeutics, Dr. Sandler was President and Global Head of
Oncology for Zai Lab, where he led
global oncology development for the company. Previously, Dr.
Sandler was the Senior Vice President and Global Head, Product
Development of Oncology Solid Tumors at Genentech, a member of the
Roche Group. He has also held academic roles at Oregon Health and
Science University, Indiana University
and Vanderbilt University. Dr. Sandler
holds an M.D. from Rush Medical College and completed his training
in internal medicine and a fellowship in medical oncology at
Yale-New Haven Medical Center. He has published over 300
publications including peer-reviewed articles, reviews, abstracts
and book chapters.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are rethinking drug development by seeking
out innovative, selective cancer therapies that can be matched to a
patient's unique tumor characteristics. Our lead candidate,
EO-3021, is a potential best-in-class antibody drug conjugate (ADC)
designed to target Claudin 18.2, a clinically validated oncology
target. EO-3021 selectively delivers a cytotoxic payload directly
to cancer cells expressing Claudin 18.2. We are evaluating EO-3021
in a Phase 1 study in patients with advanced, unresectable or
metastatic solid tumors likely to express Claudin 18.2 including
gastric, gastroesophageal junction, pancreatic or esophageal
cancers. We are also exploring other opportunities through new or
existing partnerships and business development opportunities to
expand our oncology pipeline. For more information, visit
www.ElevationOncology.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated clinical and preclinical development
activities, expected timing of announcements of clinical results
and trial details, potential benefits of Elevation Oncology's
product candidates, potential market opportunities for Elevation
Oncology's product candidates and the ability of Elevation
Oncology's product candidates to treat their targeted indications.
All statements other than statements of historical fact are
statements that could be deemed forward-looking statements. These
forward-looking statements may be accompanied by such words as
"aim," "anticipate," "believe," "could," "estimate," "expect,"
"forecast," "goal," "intend," "may," "might," "plan," "possible,"
"potential," "will," "would," and other words and terms of similar
meaning. Although Elevation Oncology believes that the expectations
reflected in such forward-looking statements are reasonable,
Elevation Oncology cannot guarantee future events, results,
actions, levels of activity, performance or achievements, and the
timing and results of biotechnology development and potential
regulatory approval are inherently uncertain. Forward-looking
statements are subject to risks and uncertainties that may cause
Elevation Oncology's actual activities or results to differ
significantly from those expressed in any forward-looking
statement, including risks and uncertainties related to Elevation
Oncology's ability to advance its product candidates, the timing
and results of preclinical studies and clinical trials, approvals
and commercialization of product candidates, the receipt and timing
of potential regulatory designations, Elevation Oncology's ability
to fund development activities and achieve development goals,
Elevation Oncology's ability to protect intellectual property,
Elevation Oncology's ability to establish and maintain
collaborations with third parties, and other risks and
uncertainties described under the heading "Risk Factors" in
documents Elevation Oncology files from time to time with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date of this press release, and
Elevation Oncology undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after
the date hereof.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-appoints-experienced-clinical-development-leaders-julie-cherrington-phd-and-alan-sandler-md-to-board-of-directors-302077109.html
SOURCE Elevation Oncology